Health Care & Life Sciences » Biotechnology | Bavarian Nordic A/S

Bavarian Nordic A/S

Bavarian Nordic A/S ADR
Stock Exchange Other OTC
EPS
 $0.45
Market Cap
 $814.76 M
Shares Outstanding
 96.74 M
Public Float
 -
Bavarian Nordic A/S
Stock Exchange Other OTC
EPS
 $1.34
Market Cap
 $726.07 M
Shares Outstanding
 32.25 M
Public Float
 -
Bavarian Nordic A/S
Stock Exchange Copenhagen Stock Exchange
EPS
 DKK8.65
Market Cap
 DKK5.42 B
Shares Outstanding
 32.32 M
Public Float
 30.3 M
Bavarian Nordic A/S
Stock Exchange Frankfurt Stock Exchange
EPS
 -
Market Cap
 -
Shares Outstanding
 32.31 M
Public Float
 -

Profile

Address
Hejreskovvej 10A
Kvistgaard CR 3490
Denmark
Employees -
Website http://www.bavarian-nordic.com
Updated 07/08/2019
Bavarian Nordic A/S focuses on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. It specializes in cancer immunotherapy which includes cancer pipeline, which focuses on therapeutic vaccines for breast, lung, ovarian and prostate cancer. Its products include IMVAMUNE for Ebola, HPV, HBV, and HIV diseases.

Financials

View All
Created with Highcharts 5.0.14Bavarian Nordic A/SNet Income. Fiscal year is January-December. All values DKK Millions.47472626595931311811813623622013201420152016201720180100200300400
Created with Highcharts 5.0.14Bavarian Nordic A/SSales/Revenue. Fiscal year is January-December. All values DKK Millions.1 2131 2131 2171 2171 0211 0211 0071 0071 3701 3705005002013201420152016201720180250500750100012501500

Gerardus Wilhelmus Maria van Odijk
Chairman
Elizabeth McKee Anderson
Independent Director
View All

StatInvestor

Privacy Policy
Feedback

© 2025 StatInvestor All Rights Reserved.